| The clinical application of etanercept in Chinese patients with rheumatic diseases. | |
| | |
MedLine Citation:
|
PMID: 16906369 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Over a 2-year period, to evaluate the efficacy and safety of biologic agents, etanercept (25 mg twice per week, s.c.) was used to treat 57 rheumatoid arthritis (RA) patients, 9 ankylosing spondylitis (AS) patients, 6 psoriatic arthritis (PSA) patients, and 4 juvenile rheumatoid arthritis (JRA) patients. In addition to inflammatory arthritis, I have used this tumor necrosis factor (TNF) blocker in other rheumatic diseases including idiopathic thrombocytopenic purpura (ITP), Behçet's disease with intractable oral ulcer, fibromyalgia syndrome, and systemic lupus erythematosis with intractable pleural effusion and acute lumbar disc herniation. For RA, after 6 months of etanercept treatment, all the parameters including number of swollen joints, number of tender joints, disease activity score, erythrocyte sedimentation rate, C-reactive protein, and global health status were rapidly improved (P < 0.001 or P < 0.0001). The anticyclic citrullinated peptide (anti-CCP) antibody and rheumatoid factor also significantly declined. For spondyloarthropathy, it also gave a similar effect as to RA. Both Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index also improved. One of the two cases with Behçet's disease with intractable oral ulcer had a long-term remission after etanercept. The other Behçet's disease patient with oral ulcer and another with ITP obtained a good response temporarily. The short-term use of etanercept (<3 months) did not bring a significant effect for cases of fibromyalgia syndrome, pleural effusion, and lumbar disc herniation. In conclusion, a dramatic and rapid clinical response in different kinds of arthritis patients can be achieved by etanercept. Moreover, the TNF-alpha inhibitor also can treat other severe rheumatic-related symptoms. In general, except for a few cases with infection and two cases with malignancy, etanercept was safe in our arthritis patients. We need to study a larger number of patients in order to better understand the efficacy and safety of etanercept. |
| | |
Authors:
|
Chung-Tei Chou |
Related Documents
:
|
4009069 - Atypical presentation of ankylosing spondylitis: a case study. 11600989 - Office-based arthroscopic synovectomy of the wrist in rheumatoid arthritis. 7488289 - Association of hla-b39 with hla-b27-negative ankylosing spondylitis and pauciarticular ... 12810429 - Antibiotic treatment and long term prognosis of reactive arthritis. 850779 - Chemical synovectomy with varicocid in rheumatoid arthritis--further results. 17973269 - Talk the walk: the importance of teaching patients how to use their walking stick effec... 16539279 - Circulating levels of beta2-glycoprotein i in thrombotic disorders and in inflammation. 7871949 - Hematuria in sickle cell anemia--not always benign: evidence for excess frequency of si... 22916049 - A case of drug-induced hepatitis due to bortezomib in multiple myeloma. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Modern rheumatology / the Japan Rheumatism Association Volume: 16 ISSN: 1439-7595 ISO Abbreviation: Mod Rheumatol Publication Date: 2006 |
Date Detail:
|
Created Date: 2006-08-14 Completed Date: 2006-10-18 Revised Date: 2007-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 100959226 Medline TA: Mod Rheumatol Country: Japan |
Other Details:
|
Languages: eng Pagination: 206-13 Citation Subset: IM |
Affiliation:
|
Division of Allergy-Immunology-Rheumatology, Veterans General Hospital Taipei, No. 201, Sec. 2, Shipai Road, Beitou Chiu, Taipei, 112, Taiwan. ctchou@vghtpe.gov.tw |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antirheumatic Agents / administration & dosage*, adverse effects Arthritis, Juvenile Rheumatoid / drug therapy, physiopathology Arthritis, Psoriatic / drug therapy, physiopathology Arthritis, Rheumatoid / drug therapy, physiopathology Asian Continental Ancestry Group Behcet Syndrome / drug therapy, physiopathology Female Fibromyalgia / drug therapy, physiopathology Humans Immunoglobulin G / administration & dosage*, adverse effects Lupus Erythematosus, Systemic / drug therapy, physiopathology Male Middle Aged Purpura, Thrombocytopenic, Idiopathic / drug therapy, physiopathology Receptors, Tumor Necrosis Factor / administration & dosage* Rheumatic Diseases / drug therapy*, physiopathology Spondylitis, Ankylosing / drug therapy, physiopathology Taiwan Treatment Outcome Tumor Necrosis Factor-alpha / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cartilage destruction by matrix degradation products.
Next Document: Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate...